Neratinib and the Role of Anti‐HER2 Therapy in Salivary Duct Carcinoma
Neratinib and the Role of Anti‐HER2 Therapy in Salivary Duct Carcinoma
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
ABSTRACT
Backgroud
Salivary duct carcinoma (SDC) is a rare and aggressive malignancy with a generally dismal prognosis and no standard of care established, despite a known association with epidermal growth factor receptor 2 (HER2) and androgen receptor (AR) over‐expression.
Case
We report the case of a 64‐year‐old female with extra‐ and...
Alternative Titles
Full title
Neratinib and the Role of Anti‐HER2 Therapy in Salivary Duct Carcinoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_aa47aebe2fcb48acbd56af12d654fe5a
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_aa47aebe2fcb48acbd56af12d654fe5a
Other Identifiers
ISSN
2573-8348
E-ISSN
2573-8348
DOI
10.1002/cnr2.70065
